An investor in NASDAQ:CXRX shares filed a lawsuit in New York over alleged violations of Federal Securities Laws by Concordia International.
Investors who purchased shares of Concordia International Corp (NASDAQ:CXRX) have certain options and for certain investors are short and strict deadlines running. Deadline: October 14, 2016. NASDAQ:CXRX investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The plaintiff claims that between November 12, 2015, and August 12, 2016 the defendants made false and/or misleading statements and/or failed to disclose that the Company was experiencing a substantial increase in market competition against the Company’s drug, Donnatal, and other products, that , as a result, the Company’s financial results would suffer, and the Company would be forced to suspend its dividend, and that, as a result of the foregoing, Defendants’ statements about Concordia’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On August 12, 016, Concordia International Corp announced its second quarter 2016 results. Among other things, Concordia International Corp also updated its full year 2016 financial guidance and announced that Adrian de Saldanha, Concordia’s Chief Financial Officer, was leaving the Company, and that Concordia’s Board unanimously agreed to suspend the Company’s $0.075 quarterly dividend.
On August 26, 2016, NASDAQ:CXRX shares closed at $8.84 per share.
Those who purchased NASDAQ:CXRX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego